# Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

> **NCT06860984** · PHASE3 · RECRUITING · sponsor: **Tanta University** · enrollment: 44 (estimated)

## Conditions studied

- Biliary Disease

## Interventions

- **DRUG:** Duloxetine
- **OTHER:** Placebo capsule

## Key facts

- **NCT ID:** NCT06860984
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2026-06-20
- **Final completion:** 2026-07-10
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06860984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06860984, "Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06860984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*